Potential new therapeutic target for Alzheimer's disease: Glucagon-like peptide-1

Xiao-Yu Liu; Ni Zhang; Sheng-Xiao Zhang; Ping Xu

doi:10.1111/ejn.15502

Potential new therapeutic target for Alzheimer's disease: Glucagon-like peptide-1

Eur J Neurosci. 2021 Nov;54(10):7749-7769. doi: 10.1111/ejn.15502. Epub 2021 Nov 7.

Authors

Xiao-Yu Liu¹, Ni Zhang¹, Sheng-Xiao Zhang^{2

3}, Ping Xu¹

Affiliations

¹ Department of Neurology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
² Department of Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
³ Key laboratory of Cellular Physiology, Shanxi Medical University, Ministry of Education, Shanxi, China.

PMID: 34676939
DOI: 10.1111/ejn.15502

Abstract

Increasing evidence shows a close relationship between Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM). Recently, glucagon-like peptide-1 (GLP-1), a gut incretin hormone, has become a well-established treatment for T2DM and is likely to be involved in treating cognitive impairment. In this mini review, the similarities between AD and T2DM are summarised with the main focus on GLP-1-based therapeutics in AD.

Keywords: Alzheimer's disease; glucagon-like peptide-1; learning and memory; neuroprotection; type 2 diabetes mellitus.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Alzheimer Disease* / drug therapy
Cognitive Dysfunction*
Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptide 1
Humans

Substances

Glucagon-Like Peptide 1